This bill amends Title XIX of the Social Security Act and related statutes to require coverage of an annual lung cancer screening — when recommended by U.S. Preventive Services Task Force guidance — across Medicaid (including managed care), Medicare, Medicare Advantage, and private group and individual plans. It bars cost‑sharing for that screening in Medicaid, removes prior‑authorization and similar utilization‑management barriers for the screening in multiple programs, and extends Medicaid coverage of counseling and pharmacotherapy for tobacco cessation to all enrollees.
The measure also directs HHS to run a targeted education and outreach campaign (authorized at $10 million per year, FY2026–2030) to increase screening uptake and tasks the Government Accountability Office with a one‑year study identifying populations missed by current screening eligibility. The bill takes effect January 1, 2026, with a standard state‑legislative‑implementation grace period where applicable.
At a Glance
What It Does
The bill adds annual lung cancer screening to mandatory Medicaid benefits (amending 1905(a)(4)), prohibits cost sharing for that screening under Medicaid payment rules, and requires Medicaid managed care contracts to cover it without prior authorization. It likewise creates a Medicare rule eliminating prior authorization for these screenings, and bars prior authorization for the screening in private group and individual plans under the PHSA.
Who It Affects
Directly affects Medicaid enrollees who meet USPSTF screening criteria, Medicaid managed care organizations, state Medicaid programs, Medicare beneficiaries and Advantage plans, private insurers in the individual and group markets, and providers that deliver low‑dose CT screening and tobacco‑cessation services.
Why It Matters
By removing cost and administrative barriers the bill aims to increase screening uptake among eligible, often low‑income populations and expand access to cessation treatments. It also creates cross‑program uniformity on prior‑authorization prohibitions — a notable federal intervention into utilization management that could shift program spending and provider workflow.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
At its core the bill makes annual lung cancer screening recommended by the US Preventive Services Task Force a covered, mandatory benefit under Medicaid and removes three common barriers to access: cost sharing, prior authorization, and managed‑care gatekeeping. Practically, it inserts a new clause into section 1905(a)(4) of the Social Security Act to classify the screening as a Medicaid benefit and changes payment and cost‑sharing provisions so states cannot impose copays or alternative cost‑sharing arrangements for that service.
The legislation also expands Medicaid’s coverage of tobacco‑cessation counseling and pharmacotherapy. Existing statutory language had tied comprehensive cessation coverage largely to pregnant women; this bill removes that restriction and requires coverage for counseling and FDA‑approved pharmacotherapies for cessation for all Medicaid enrollees, and it prevents states and managed care plans from using prior authorization to block those services.For Medicare, the bill adds a new special rule to section 1834 that prohibits prior authorization for annual lung cancer screening when the Secretary has adopted USPSTF‑aligned guidance, and it carries the same prohibition into Medicare Advantage plan contract requirements.
In the commercial market the bill amends the preventive services statute (PHSA 2713) to bar prior authorization for USPSTF‑recommended annual lung cancer screening in group and individual plans.Beyond coverage rules, the bill dedicates federal money and programmatic attention: $10 million per year (FY2026–2030) for HHS to run targeted education and outreach aimed at high‑risk populations, and a GAO study within one year to map who is being diagnosed versus who is being screened, with an explicit instruction to identify groups not captured by current USPSTF eligibility (examples flagged in the bill include firefighters and veterans). The statutory effective date is January 1, 2026, with a standard allowance where states need legislative action to conform their plans.
The Five Things You Need to Know
Section 1905(a)(4)(G) — adds annual lung cancer screening as a mandatory Medicaid benefit for individuals recommended by USPSTF guidance.
Medicaid cost‑sharing ban — amends section 1916 to prohibit cost sharing and alternative cost‑sharing arrangements for the screening (and applies the rule in Medicaid managed care contexts).
Prior‑authorization prohibition — requires Medicaid MCO contracts, Medicare fee‑for‑service (new 1834(z)), Medicare Advantage contracts, and group/individual private plans (PHSA 2713(d)) to refrain from imposing prior authorization for USPSTF‑recommended annual lung cancer screenings.
Tobacco‑cessation expansion — removes the pregnant‑women limitation and requires counseling and pharmacotherapy for tobacco cessation for all Medicaid enrollees, with no prior authorization for those services.
Outreach and study — authorizes $10 million annually for HHS outreach (FY2026–2030) and directs the GAO to report within one year on screening demographics and populations missed by current eligibility.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Medicaid coverage and removal of prior authorization for lung cancer screening
This section amends 1905(a)(4) to add an express Medicaid benefit category for annual lung cancer screening tied to USPSTF recommendations, and alters 1916 and 1916A to exclude that screening from cost‑sharing and alternative cost‑sharing rules. It also amends 1932(b) to require Medicaid managed care contracts to cover the screening and not condition coverage on prior authorization. For administrators: the change converts what may have been discretionary coverage into a mandatory, no‑cost‑sharing benefit and restricts plan-level utilization controls for that service.
Expand Medicaid cessation services to all enrollees
Section 3 removes statutory language that limited comprehensive tobacco‑cessation counseling and pharmacotherapy to pregnant women and rewrites related sections of 1916 and 1927 to require coverage for counseling and cessation drugs for all Medicaid beneficiaries. It also bars prior authorization for those cessation services and requires managed care contracts to offer them. Operationally, states must update formularies and benefit descriptions and MCOs must change utilization rules to comply.
Medicare and private‑market prohibitions on utilization management
This section creates a specific Medicare provision (new 1834(z)) that prevents application of prior authorization for annual lung cancer screening aligned with Secretary/USPSTF guidance and adds an MA plan restriction in 1852(a). It mirrors that prohibition in the commercial market by amending PHSA 2713 to prevent prior authorization for the screening in group and individual plans. The net effect is a cross‑system restriction on a common utilization‑management tool for this one preventive service.
HHS education, targeted outreach, and funding
HHS must conduct an education and outreach campaign, developed with patient and lung‑cancer advocacy groups, focused on high‑risk populations and providers. The bill authorizes $10 million per fiscal year from 2026 through 2030 to support this work and permits HHS to use contracts, grants, or direct action. The appropriation is programmatic — it funds outreach activities rather than changing reimbursement — and will require HHS to prioritize reach into populations with access barriers.
GAO study on screening demographics and gaps
The Comptroller General must produce a report within one year describing who is screened and who is diagnosed with lung cancer, and specifically identify groups that fall outside current USPSTF eligibility (the bill cites firefighters, veterans, and younger women as examples). The report must recommend federal actions to improve screening for those groups — a congressional information tool that could catalyze later regulatory or statutory changes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicaid beneficiaries who meet USPSTF criteria — they gain guaranteed yearly coverage of low‑dose CT screening with no Medicaid cost sharing and fewer administrative blockers to access.
- Smokers and people seeking cessation — all Medicaid enrollees become eligible for counseling and pharmacotherapy without prior authorization, increasing access to evidence‑based quitting tools.
- Screening providers and community health clinics — likely higher referral volumes and steadier reimbursement for covered LDCT screenings as payors cannot impose prior authorization or copayments for eligible patients.
- High‑risk outreach targets and advocacy groups — federal funding for targeted education campaigns should increase community outreach capacity and awareness among under‑screened populations.
Who Bears the Cost
- State Medicaid programs — states will shoulder added service utilization and pharmaceutical costs for an expanded benefit set unless matched by federal offsets; they also must update plans and contracts to comply.
- Medicaid managed care organizations — MCOs lose prior‑authorization as a utilization management lever for these services, which may increase their medical spend and administrative workload.
- Private insurers and Medicare Advantage plans — must eliminate prior authorization for the screening within their covered populations, potentially increasing utilization and near‑term costs.
- Federal agencies — HHS must design and implement the outreach program and the GAO must conduct the study, both requiring staff time and administrative resources tied to the authorized funding.
Key Issues
The Core Tension
The central dilemma is improving equitable access to an evidence‑based preventive service by removing financial and administrative barriers versus preserving payors’ ability to manage clinical appropriateness and program costs; the bill prioritizes access and standardization but leaves states, plans, and providers to absorb cost, capacity, and enforcement challenges without detailed implementation guardrails.
The bill forces a trade‑off between increasing access and restricting utilization management. Removing prior authorization and cost sharing will lower access barriers, but it also eliminates common tools payors use to manage inappropriate or duplicative use.
That raises open implementation questions: how will clinicians document eligibility under USPSTF guidance at point of care, and what audits or post‑payment controls will states and plans use to prevent inappropriate billing? The statute does not specify documentation standards, coding guidance, or enforcement mechanisms, leaving states, CMS, and payors to fill those gaps through guidance or policy changes.
Financial impacts are uneven. While federal mandates standardize coverage, they transfer immediate cost pressure to states and managed care plans that already face tight budgets.
The expansion of cessation pharmacotherapy will raise prescription spending for Medicaid unless offset by higher federal match or managed‑care premium adjustments. Capacity constraints are another practical concern: a rapid increase in LDCT demand may strain radiology services and require investments in quality assurance to avoid variable scan interpretation and false positives.
Finally, the bill ties coverage to USPSTF recommendations; changes in task force guidance (age and risk‑factor thresholds) will alter who benefits, and the statute does not create a mechanism to harmonize emerging evidence, workforce readiness, or payment reforms alongside coverage changes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.